XTL BIOPHARMACEUTICALS LTD.
Income Statement
| Line Item | FY2024 |
|---|---|
| Revenue | $451.0K |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | — |
| SG&A Expense | — |
| Operating Income | $-2.2M |
| Operating Margin | -481.6% |
| Interest Expense | $28.0K |
| Pretax Income | $-1.2M |
| Income Tax Expense | $-130.0K |
| Net Income | $-1.0M |
| Net Margin | -227.7% |
| EPS (Basic) | $0.00 |
| EPS (Diluted) | $0.00 |
| Shares Outstanding (Basic) | 881.4M |
| Shares Outstanding (Diluted) | 881.4M |
| Dividends Per Share | — |